LLY

1,006.06

+1.27%↑

JNJ

209.91

+1.6%↑

ABBV

223.8

-0.55%↓

UNH

336.55

+2.68%↑

AZN

90.26

-1.28%↓

LLY

1,006.06

+1.27%↑

JNJ

209.91

+1.6%↑

ABBV

223.8

-0.55%↓

UNH

336.55

+2.68%↑

AZN

90.26

-1.28%↓

LLY

1,006.06

+1.27%↑

JNJ

209.91

+1.6%↑

ABBV

223.8

-0.55%↓

UNH

336.55

+2.68%↑

AZN

90.26

-1.28%↓

LLY

1,006.06

+1.27%↑

JNJ

209.91

+1.6%↑

ABBV

223.8

-0.55%↓

UNH

336.55

+2.68%↑

AZN

90.26

-1.28%↓

LLY

1,006.06

+1.27%↑

JNJ

209.91

+1.6%↑

ABBV

223.8

-0.55%↓

UNH

336.55

+2.68%↑

AZN

90.26

-1.28%↓

Search

Maravai LifeSciences Holdings Inc (Class A)

Cerrado

3.7 -0.27

Resumen

Variación precio

24h

Actual

Mínimo

3.58

Máximo

3.74

Métricas clave

By Trading Economics

Ingresos

44M

-26M

Ventas

-5.8M

42M

Margen de beneficio

-61.388

Empleados

550

EBITDA

44M

-22M

Recomendaciones

By TipRanks

Recomendaciones

Comprar

Estimación a 12 meses

+8.4% upside

Estadísticas de Mercado

By TradingEconomics

Capitalización de Mercado

246M

1.3B

Apertura anterior

3.97

Cierre anterior

3.7

Puntuación técnica

By Trading Central

Confianza

Bullish Evidence

Maravai LifeSciences Holdings Inc (Class A) Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

10 dic 2025, 22:02 UTC

Ganancias

Synopsys Sees Strong 2026 as Ansys Acquisition Boosts 4Q Revenue

10 dic 2025, 21:46 UTC

Ganancias

Adobe Expects Double-Digit Recurring Revenue Growth Next Year

10 dic 2025, 23:52 UTC

Adquisiciones, fusiones, absorciones

Paramount Sends Letter to Warner Bros. Shareholders Saying Its Offer Is 'Superior' -- Barrons.com

10 dic 2025, 23:43 UTC

Charlas de Mercado

Nikkei May Rise After Fed Rate Cut -- Market Talk

10 dic 2025, 23:36 UTC

Charlas de Mercado

Gold Consolidates as Traders Digest FOMC Decision -- Market Talk

10 dic 2025, 23:20 UTC

Ganancias

Oracle Reports $16.1 Billion in Revenue, Narrowly Missing Forecasts -- 2nd Update

10 dic 2025, 23:15 UTC

Ganancias

Synopsys Targets Double-Digit Growth Following Ansys Acquisition -- Interview

10 dic 2025, 22:59 UTC

Charlas de Mercado
Ganancias
Adquisiciones, fusiones, absorciones

Adobe Expects Semrush Deal to Bring in New Users -- Market Talk

10 dic 2025, 22:45 UTC

Charlas de Mercado

Coca-Cola's New CEO Pick Looks A Lot Like The Last One -- Market Talk

10 dic 2025, 22:40 UTC

Ganancias

Synopsys Stock Rises on Earnings Beat, Higher Guidance -- Barrons.com

10 dic 2025, 22:06 UTC

Adquisiciones, fusiones, absorciones

Paramount Sends Letter to Warner Bros. Shareholders Saying Their Offer Is 'Superior' -- Barrons.com

10 dic 2025, 22:06 UTC

Ganancias

Oracle Reports Mixed Earnings. The Stock Is Falling. -- Barrons.com

10 dic 2025, 22:02 UTC

Ganancias

Synopsys Stock Rises on Earnings Beat, Higher Guidance -- Barrons.com

10 dic 2025, 22:00 UTC

Ganancias

Oracle Reports $16.1 Billion in Revenue, Narrowly Missing Forecasts -- Update

10 dic 2025, 21:53 UTC

Ganancias

Adobe Earnings Show 'Rapid Adoption' of AI Tools. The Stock Is Up. -- Barrons.com

10 dic 2025, 21:50 UTC

Adquisiciones, fusiones, absorciones

Investors Bet That a Higher Bid for Warner Is Coming -- Update

10 dic 2025, 21:50 UTC

Charlas de Mercado
Ganancias
Adquisiciones, fusiones, absorciones

Financial Services Roundup: Market Talk

10 dic 2025, 21:50 UTC

Charlas de Mercado

Health Care Roundup: Market Talk

10 dic 2025, 21:50 UTC

Charlas de Mercado

Auto & Transport Roundup: Market Talk

10 dic 2025, 21:45 UTC

Adquisiciones, fusiones, absorciones

Paramount Sends Letter to Warner Bros. Shareholders Saying Their Offer Is 'Superior' -- Barrons.com

10 dic 2025, 21:33 UTC

Ganancias

Oracle Reports $16.1 Billion in Revenue, Narrowly Missing Forecasts -- WSJ

10 dic 2025, 21:32 UTC

Ganancias

Oracle Reports Mixed Earnings. The Stock Is Falling. -- Barrons.com

10 dic 2025, 21:28 UTC

Adquisiciones, fusiones, absorciones

Sverica Capital Management Announces Sale of Coastal Cloud Holdings to Tata Consultancy Services for $700M

10 dic 2025, 21:25 UTC

Ganancias

Adobe Earnings Show 'Rapid Adoption' of AI Tools. The Stock Is Up. -- Barrons.com

10 dic 2025, 21:18 UTC

Adquisiciones, fusiones, absorciones

Paramount Skydance: Company Has Air Tight Financing to Deliver on Warner Bros. Offer >PSKY

10 dic 2025, 21:16 UTC

Ganancias

Oracle Reports Mixed Earnings. The Stock is Falling. -- Barrons.com

10 dic 2025, 21:15 UTC

Adquisiciones, fusiones, absorciones

Paramount Skydance: Public Offer for Warner Bros. Delivers Superior Value, Faster, More Certain Path to Completion

10 dic 2025, 21:15 UTC

Ganancias

Oracle: 'Sold Ampere Because We No Longer Think It Is Strategic for Us to Continue Designing, Manufacturing and Using Our Own Chips in Our Cloud Datacenters' >ORCL

10 dic 2025, 21:14 UTC

Ganancias

Oracle 2Q Non-GAAP Operating Income Was $6.7 B >ORCL

10 dic 2025, 21:14 UTC

Ganancias

Oracle 2Q GAAP Operating Income Was $4.7 B >ORCL

Comparación entre iguales

Cambio de precio

Maravai LifeSciences Holdings Inc (Class A) Esperado

Precio Objetivo

By TipRanks

8.4% repunte

Estimación a 12 meses

Media 4 USD  8.4%

Máximo 4 USD

Mínimo 4 USD

De acuerdo con 3 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Maravai LifeSciences Holdings Inc (Class A) Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

3 ratings

2

Comprar

1

Mantener

0

Vender

Puntuación técnica

By Trading Central

2.02 / 2.115Soporte y Resistencia

Corto Plazo

Bullish Evidence

Medio plazo

Strong Bullish Evidence

Largo Plazo

No Evidence

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Maravai LifeSciences Holdings Inc (Class A)

Maravai LifeSciences Holdings, Inc., a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species. It operates in two segments, Nucleic Acid Production and Biologics Safety Testing. The Nucleic Acid Production segment manufactures and sells products for use in the fields of gene therapy, vaccines, nucleoside chemistry, oligonucleotide therapy, and molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling, and purification of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). This segment also offers messenger RNA, oligonucleotides, and oligonucleotide building blocks, as well as custom enzyme development and manufacturing and CleanCap capping technology. The Biologics Safety Testing segment sells analytical products for use in biologic manufacturing process development, including custom product-specific development antibody, and assay development services. This segment also provides HCP ELISA kits, other bioprocess impurity and contaminant ELISA kits, ancillary reagents, viral clearance prediction kits, and custom services. The company serves biopharmaceutical companies, and other biopharmaceutical and life sciences research companies; and academic research institutions and in vitro diagnostics companies. The company was incorporated in 2020 and is headquartered in San Diego, California.
help-icon Live chat